tbuckley/cabot-search huggingface dataset:
AB0909 The Jadas in Assessing the Activity of Juvenile Idiopathic Arthritis: Jadas ESR versus Crp
Authors: M.E.I. Fanata, A. Bouchra, R. Samira, E.B. Dalal, M. Nada, E. Majda, S. Siham, G. Sanae, W. Moudjibou, H.-H. Najia
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The Jadas (Juvenile arthritis Disease Activity Score) is a recently developed and validated for the assessment of the activity of juvenile idiopathic arthritis (JIA) composite score it includes 4items. Articular index, physician global assessment, overall assessment relatives of patients, and the erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) has been suggested as a marker of inflammation alternative to ESR <h3>Objectives</h3> To compare the scores of JADAS ERS versus CRP in assessing the activity of JIA. <h3>Methods</h3> Cross-sectional study including 47 patients aged less than 18 years, suffering from juvenile idiopathic arthritis, defined according to the 2001 ILAR classification. Sociodemographic parameters, clinical and para- clinical trials relating to patients were collected. 24 patients had an ESR and CRP measures. The Jadas 10-ESR and Jadas 10-CRP were used to assess disease activity. The scores of Jadas 10 ESR and CRP were calculated as a simple linear sum of their 4 components, giving a total score of 0-40, with higher scores corresponding to a severe disease activity. A descriptive and analytical statistical analysis was performed. <h3>Results</h3> 47 patients were included with a male predominance n=28 (59.6%). the average age was 11.59 years ±3.35; 40 patients (85.1%) were scholed.The disease duration of JIA had a median of 4 years [2-6], with predominance of oligoarthritis persistent n=12 (26.7%) the median overall EVA patient was 20 [10-40]. The mean of DAS28 was 3.1±1.5 and the median of JADAS10 ESR was 11.2 [5.38], the median of JADAS10-CRP was 12 [9-15], and the correlation between Jadas 10-ESR and Jadas 10- CRP was not statistically significant; it was not found significant statistical association between JADAS10 -CRP with clinical parameters, and other means of assessment of the activity of JIA as well as different types of JIA. <h3>Conclusions</h3> Our study showed no significant correlation between the two types of Jadas in different clinical forms. The limited number of our patients encourages us to make further larger studies to prove the superiority of one Jadas compared to another <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5359
Incidental Detection of Clinically Nondiagnosed Inguinal Hernia in 131I Whole-Body Scan
Authors: Anbalagan Kannivelu, Butch Magsombol, Ajit Kumar Padhy
Journal: Clinical Nuclear Medicine (2013)

131I whole-body bone scan was performed for an adult male patient after postradioactive iodine ablation of thyroid carcinoma. Besides the small thyroid remnants in the neck region, an incidental detection of left inguinal hernia was made in the scan, which was later confirmed by clinical examination. Despite the large size of the hernia, the patient was unaware of the condition. It can be concluded that, similar to other imaging procedures, incidental detection of unrelated clinical problems is possible in 131I scan also, and such early diagnosis prevents further complications that the patient may develop in the future.
Abstract 4295: The combination of a novel anti-delta-like 4 ligand (DLL4) antibody with irinotecan inhibits growth of Kras-mutated colorectal tumors
Authors: Marcus Fischer, Wan-Ching Yen, John Lewicki, Austin Gurney, Timothy Hoey
Journal: Cancer Research (2010)

Abstract Kras mutations in colorectal cancer (CRC) are associated with clinical resistance to treatment with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies. It has been suggested that cancer stem cells drive tumor growth and progression and are preferentially resistant to many current therapies. Delta-like 4 ligand (DLL4) is an important component of the Notch signaling pathway which is known to mediate stem cell self-renewal and vascular development. We have recently demonstrated that inhibition of human DLL4 in the tumor reduced cancer stem cell frequency, whereas inhibition of mouse DLL4 resulted in hyperproliferation of the tumor vasculature (Cell Stem Cell, 5:168-177, 2009). The goal of the present study is to extend the utility of anti-DLL4 in treatment of mutant Kras CRC. Consistent with clinical findings, mutant Kras colorectal xenograft tumors were generally insensitive to EGFR-targeted monoclonal antibody cetuximab and addition of anti-DLL4 did not further enhance cetuximab-mediated anti-tumor effect. In contrast, anti-DLL4 plus irinotecan was equally efficacious against both wild type and mutant Kras colon tumors. Gene expression analysis showed that anti-DLL4 affected vascular-related genes in the stroma and Notch target genes in the tumor and stroma. Further analysis of mutant Kras tumors indicated that anti-DLL4/ irinotecan combination produced a 5-fold decrease in colon cancer stem cell frequency compared to control antibody treated group. In conclusion, our findings provide a rationale for targeting cancer stem cells and tumor vasculature through inhibition of the DLL4/Notch signaling for treatment of CRC patients with Kras mutation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4295.
Hypermetabolism During Resting-State FDG-PET Suggesting Intrinsic Epileptogenicity in Focal Cortical Dysplasia
Authors: Izzie Jacques Namer, Maria Paola Valenti-Hirsch, Julia Scholly, Béatrice Lannes, Alessio Imperiale, Edouard Hirsch
Journal: Clinical Nuclear Medicine (2014)

We report the case of a 21-year-old man who presented drug-resistant epilepsy since the age of 3 years. The underlying type Ia left prefrontal focal cortical dysplasia was revealed by focal hypermetabolism of FDG-PET several years later. The stereo-electroencephalography showed continuous interictal rhythmic spike discharges, suggesting the dysplastic character of the cortex explored by depth electrodes placed into and at the margins of PET abnormalities. The surgical limits of resection were defined based on interictal activity, spontaneous and induced seizures. The patient is seizure-free, with normal electroencephalography and clear improvement of neuropsychological performance, without functional deficit at 3 years postsurgery.
Carmustine-methotrexate combination in breast cancer patients presenting with brain metastases.
Authors: W Jacot, M Gerlotto-Borne, S Thezenas, S Pouderoux, M About, G Romieu
Journal: Cancer Research (2009)

Abstract Abstract #6119 Purpose: There is currently no standard chemotherapy regimen for breast cancer (BC) patients presenting with brain metastases (BM). Since 1999, in our institution, these patients are treated with an association of carmustine (BCNU) and methotrexate (MTX). We report here the efficacy and safety profile of this association. Patients and methods: In this study, BC patients presenting with BM were treated by an association of BCNU 100 mg/m² on day 1 and MTX 600 mg/m² on day 1 and 15 of a 28 days cycle. Treatment was continued until progression or unacceptable toxicity. In order to evaluate this combination, we analyzed activity by recording tumor response rates, progression-free survival (PFS) and overall survival (OS), treatment compliance by analyzing Relative Dose Intensity (RDI) and safety by analyzing clinical and biological toxicities using NCI CTCAE v3.0. Results: Fifty patients were treated between 1999 and 2007, with a median age of 52 years (range 26-77 years). Median time between diagnosis of BC and BM was 37 months (0-180). One patient had synchronous BM. No tumor was recorded to be Scarf, Bloom and Richardson grade I, 40% were hormonal receptor negative and 50% of the 36 tumors analyzed for HER-2 amplification were positive. 94% of the patients presented with concomitant extra-cerebral disease, mainly bone (76%), liver (46%), lung (42%) and lymph node (26%) metastases. The number of previous chemotherapy regimens in the metastatic setting was 2 (1-5). The median number of administered cycles of BCNU-MTX was 3 (1-20). 30% of the patients received up to 6 chemotherapy cycles, with 20% patients continuing the treatment after 6 cycles. There were 11 objective responses (23% [IC95% 12-37]) among 48 evaluable patients, with an additional 29% disease stabilization, for a total 52% of patients with clinical benefit. Median PFS and OS were 4.2 (95%CI: 2.8-5.3) and 6.9 (4.2-10.7) months respectively, with a one-year OS rate of 32% (20-46). There were 2 presumed treatment-related deaths. The median RDI for BCNU and MTX were 0.98 (0.31-1.1) and 0.96 (0.57-1.66) respectively. Treatment was well tolerated, with the most common grade 3-4 toxicities per patients as follow (%pts): anemia (8.4), neutropenia (40.4), thrombocytopenia (21.2), and grade 3 fatigue (10.6). One patient developed febrile neutropenia. Poor prognosis was associated with a poor performance status in a univariate analysis of OS.Conclusion: In this population of heavily pretreated patients affected by BM from BC, the combination of BCNU-MTX appears to be an effective and well tolerated combination in good performance status BC patients presenting with BM. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6119.
Abstract P2-14-04: Co-Administration of GnRH-Agonists with Adjuvant Chemotherapy in Young Breast Cancer Patients: The Effect on Ovarian Function and on Clinical Outcome
Authors: H Goldberg, M Stern, S Risel, A Kuten, E Evron, T Peretz, D. Katz
Journal: Cancer Research (2010)

Abstract Background: Loss of fertility is a major concern for young breast cancer (BC) patients who require adjuvant chemotherapy. The risk of ovarian failure depends on patient's age and chemotherapy regimen. Use of GnRH agonists (GnRHa) has been proposed as a mean for ovarian function preservation but has been investigated mainly in small single arm studies. Objectives: To evaluate ovarian function preservation and disease free survival (DFS) in young breast cancer patients following GnRHa and adjuvant chemotherapy co-administration. Methods: In this multicenter retrospective study, we reviewed medical records of 560 breast cancer patients diagnosed before the age of 40, from 1990 through 2006. All patients were treated in one of 5 Israeli cancer centers with standard adjuvant or neoadjuvant chemotherapy regimens with curative intent. GnRHa were prescribed at the discretion of the treating physician. Ovarian function preservation was determined by resumption of menses, premenopausal hormonal profile or pregnancy during follow up. Multivariate analysis was applied in order to determine whether coadministration of GnRHa with chemotherapy affects DFS. Results: Data was available for 71 patients who received GnRHa during chemotherapy (group A), 60 of those were evaluable for fertility and 68 were evaluated for DFS. The group not receiving GnRHa included 460 patients (group B). Of those 207 were evaluable for fertility and 370 for DFS. Data concerning patients’ characteristics and outcome in each group are presented in the table 1. In a Cox regression model including age, stage, ER/PR status and GnRHa administration, the latter variable predicted a better DFS rate (RR 0.31; 95% CI 0.16-0.70; p=0.003), excluding the subgroup with ER/PR positive tumors (p=0.128). This probably reflects selection bias of prognostic factors not included in the analysis and not a real anti neoplastic hormonal effect. Conclusions: Patients who received GnRHa were younger and had less advanced disease. Fertility was preserved independent of GnRHa administration and regardless of cumulative doses of cyclophosphamide or taxans. This observation suggests that GnRHa are unnecessary for fertility preservation in patients younger than 40yrs. No detrimental effect of GnRHa during chemotherapy was observed on disease outcome. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-14-04.
Pulmonary Shunt in a Single Lung Evidenced by Quantitative Lung Scan Obtained in the Erect and Supine Positions
Authors: S C Cherng, Y F Wang, T K Jen, S P Yang, S G Li
Journal: Clinical Nuclear Medicine (2000)

A 46-year-old woman had a nonfunctioning lung and pulmonary shunt resulting from trauma. She had shortness of breath when in the erect position but no symptoms when in the supine position. A chest radiograph and computed tomographic scan showed collapse of the left lung, hyperinflation of the right lung, and cardiomegaly. Body position and cardiomegaly are causes of nonuniform pulmonary artery perfusion revealed by quantitative lung scans obtained in different positions. After left pneumonectomy with left pulmonary artery ligation, the clinical symptoms subsided completely.
Stat Bite: Average Years of Life Lost per Person
Authors: B. F. Hankey
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Stat Bite : Average Years of Life Lost per Person Get access Benjamin F. Hankey, Sc.D. Benjamin F. Hankey, Sc.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 17, 2 September 1992, Page 1311, https://doi.org/10.1093/jnci/84.17.1311 Published: 02 September 1992
Abstract 4217: Engaging CD151 inhibits cell migration and metastasis through a novel mechanism involving the cell adhesion molecule ALCAM/CD166
Authors: Trenis D. Palmer, Antonio Mazzocca, Amanda Hansen, Shanna Arnold, Celestial Jones-Paris, Masashi Yamada, Kiyotoshi Sekiguchi, Andries Zijlstra
Journal: Cancer Research (2012)

Abstract We recently demonstrated that actively promoting the formation of cell surface complexes by engaging the tetraspanin CD151 with a monoclonal antibody (mAb 1A5) inhibits metastasis by immobilizing the tumor cells. Tetraspanins influence cellular behavior via the regulation of associated partner molecules such as integrins, cell adhesion molecules, and members of the immunoglobulin superfamily. Although CD151 is able to associate with and regulate the activity of laminin-binding integrins we demonstrate that CD151 does not associate with α3α1 in the presence of mAb 1A5. Using a 2-color flow cytometric approach we mapped the domains of CD151 required for antigen recognition by mAb 1A5 and determined that 1A5 maps to the integrin 194QRD196 motif of CD151, using this information we further performed CD151 co-immunoprecipitations and demonstrated that 1A5 recognizes CD151 not associated with α3α1.To determine the identity of the protein(s) associated with the antibody-engaged CD151 and also possibly responsible for the anti-migratory, anti-metastatic phenotype we used a proteomic approach. Using tandem mass spectrometry on CD151-associated proteins co-immunoprecipitated by mAb 1A5, we detected in excess of 200 proteins. This strategy identified several putative partners of CD151. Further analysis of the CD151 associated proteins led to our discovery of the novel CD151-associated protein ALCAM/CD166, a member of the immunoglobulin superfamily. Using an RNAi-mediated knockdown approach we demonstrate that ALCAM/CD166 is required for the CD151 complex to regulate tumor cell mobility in vitro. Conversely, CD151 is required for ALCAM to control motility. Spontaneous metastasis assays using the avian chorioallantoic membrane and subcutaneous murine xenografts demonstrate thatALCAM/CD166 is indeed required for the engaged tetraspanin to inhibit tumor cell dissemination in vivo. Further mechanistic analysis of this complex revealed that the CD151/ALCAM protein complex promotes activation of the small GTPase Rap1 via activated protein kinase C. Collectively, we present data, which demonstrate that, the ALCAM-containing CD151 complex can control metastasis. This novel complex reveals how cell-cell interactions can control migration through the regulation of cell-matrix adhesions. These results also demonstrate mechanistically that tetraspanins can integrate signaling between physically distinct molecular functions and therefore behave as a molecular clutch that controls matrix adhesion in response to cell-cell interactions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4217. doi:1538-7445.AM2012-4217
Erythema Nodosum Associated With Diffuse, Large B-Cell Non-Hodgkin Lymphoma Detected by FDG PET
Authors: Kerry A. Cheong, Nicholas G. Rodgers, Ian D. Kirkwood
Journal: Clinical Nuclear Medicine (2003)

A patient is described with non-Hodgkin lymphoma and erythematous skin nodules suspected to be erythema nodosum. The patient underwent serial fluorodeoxyglucose (FDG) positron emission tomography (PET), which demonstrated normalization of FDG uptake by the lymphoma after 2 cycles of chemotherapy, but there was new abnormal uptake involving the subcutaneous tissues of the lower extremities. A typical skin lesion was sampled and showed the appearance of erythema nodosum with no evidence of lymphoma. The FDG uptake gradually diminished on serial PET imaging after treatment with nonsteroidal antiinflammatory drugs. In view of the recognized association of erythema nodosum with malignancy and the differential rate of response to chemotherapy, the lesions of erythema nodosum may be a source of a false-positive PET interpretation, and histologic assessment should be considered.
Abstract 232: Cancer stem cells and cisplatin.
Authors: Vishnu Modur
Journal: Cancer Research (2013)

Abstract Introduction: Cisplatin is an important chemotherapeutic agent, which has resulted in higher overall response rates when combined with 5-FU or taxane combinations in treating squamous cellular carcinoma of the head and neck. However, HNSCC tumor response rates to cisplatin range from 20-30%, a major clinical hurdle today. To address this issue thoroughly, we investigated the resistance to cisplatin in HNSCC under the purview of the cancer stem cell hypothesis, using the widely studied CSC marker combinations of, CD44+ 24- and ALDH-Hi. In order to get a broader perspective on this issue, we worked on multiple HNSCC tumor cell lines with varying degrees of cisplatin resistance, arising from tumors of the pharynx, larynx, tongue, tonsils, alveolus, hypopharynx and supraglottis. Methods: Seven HNSCC cell lines were analyzed for their CSC percentage through FACS, utilizing CD44+ 24- and ALDH-Hi marker systems. Cisplatin IC-50 for each of these seven cell lines was then determined by plotting percent viability vs. drug concentration curves. The remaining viable cells after cisplatin treatment were then analyzed through FACS for their CD44+ 24- and ALDH-Hi percentages in order to compare with the CSC percentage in the untreated HNSCC lines. Results: There was a wide variation in the percentages of CD44+24- and ALDH-Hi cells across these seven HNSCC lines. An inverse correlation between the initial percentages of CD44+24- and ALDH-Hi cells and the corresponding cisplatin IC-50 values was seen. HNSCC cell lines that had lower IC-50 values for cisplatin displayed greater cell viability at higher concentrations of cisplatin. This was evident by a long tail in the sigmoidal dose response curve. The number of viable cells at the end of cisplatin treatment had a linear relationship with the overall percentage of CSCs in the control untreated cell lines. Conclusion: Our results suggest that the resistance offered by the CD44+24- and ALDH1-Hi cells is apparent only once the initial 50% loss of cells occurs. This in vitro biphasic decline in percent viable cells clearly indicates that HNSCC cisplatin resistance is a twofold problem. The bulk of non-cancer stem cells within a tumor can acquire resistance to cisplatin via multiple molecular pathways, but this is only a front line cover of resistance to the resistance offered by the cancer stem cells. Citation Format: Vishnu Modur. Cancer stem cells and cisplatin. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 232. doi:10.1158/1538-7445.AM2013-232
Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia.
Authors: S Chia, C Bryce, G Pansegrau, N Macpherson, S Ellard, D Jepson, C Yu, S Nuraney, A Attwell, M Hayes, H Kennecke, K Gelmon
Journal: Cancer Research (2009)

Abstract Abstract #5118 Background: The role of trastuzumab either concurrent or sequential with adjuvant chemotherapy have clearly demonstrated significant benefits in early stage HER-2 positive breast cancer. There is now an accumulation of phase II and III trials also demonstrating improved pathological complete responses (pCR) in HER-2 positive breast cancer with neoadjuvant trastuzumab concurrent with chemotherapy. The number of patients on these trials are significantly fewer, and many of these trials are a mixture of primary operable and LABC. We have completed a multi-centre phase II trial of neoadjuvant chemotherapy and trastuzumab in HER-2 positive LABC.&amp;#x2028; Methods: Women with HER-2 positive (IHC 3+ or FISH+) stage IIB-IIIC breast cancer were enrolled. Treatment consisted of 4 cycles of FEC100 (5-FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 4 cycles of TCH (Docetaxel 75 mg/m2, carboplatin AUC 6, trastuzumab 8 mg/kg loading then 6 mg/kg q3 weekly). Trastuzumab was also continued adjuvantly for 9 months following chemotherapy and surgery. Cardiac monitoring every 3 months was mandated. A correlative translational component with baseline and interval biopsies and serum collection was also performed.&amp;#x2028; Results: A total of 30 patients (3 stage IIB; 14 IIIA; 10 IIIB and 3 IIIC) over a 3 year time period in 4 centres were accrued. Median age was 49 years (26-77 years). 60% of tumours were ER negative. There was one clinical CHF and 2 asymptomatic falls in LVEF requiring early discontinuation of trastuzumab. There were 3 episodes (10%) of febrile neutropenia. Seven patients underwent adjuvant radiotherapy prior to surgery. The pCR rate (breast and axilla) for the entire study population was 60% (18/30). There have been 3 recurrences so far (all biopsy proven) – of which 2 were brain metastases only. Further details on toxicity and changes in LVEF will be presented.&amp;#x2028; Conclusions: This multi-centre phase II trial clearly demonstrates significant activity (pCR 60%) for neoadjuvant anthracyclines followed by concurrent taxane, platinum and trastuzumab in a HER-2 positive LABC population. Overall the treatment regimen was well tolerated. Brain metastases however appear to be a common site of relapse in this high risk patient population and further treatment strategies directed at this site should be investigated. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5118.